Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

  • Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced new efficacy data supporting the Phase 3 development of XEN1101.
  • XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses compared with placebo. 
  • At Week 1, the median percent reduction in monthly focal onset seizure frequency was 55.4% in the 25 mg group, 41.5% (20 mg), and 39.1% (10 mg) compared to 20.2% in the placebo group. 
  • Based on the data, a key secondary endpoint in the Phase 3 trials will include the median percent change of weekly FOS at Week 1.
  • Related: Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment.
  • Seizure frequency continued to improve for the open-label extension (OLE) population during the first month after the 8-week double-blind period (DBP), suggesting that the efficacy signal can persist and may improve in the planned 12-week DBP of the XEN1101 Phase 3 trials.
  • Subjects remaining in the X-TOLE OLE for at least three months and 12 months experienced a greater than 70% and 80% reduction in median monthly seizure frequency compared to the DBP baseline.
  • 54 (19.6%) and 26 (9.5%) of subjects in the OLE experienced a ≥6 and a ≥12 consecutive months of seizure freedom, respectively. 
  • Xenon also priced its underwritten public offering of 7.9 million shares and pre-funded warrants to purchase up to 327,868 shares at $30.50 per common share, with gross proceeds of $250 million.
  • Price Action: XENE shares are down 13.52% at $30.01 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.